Nuwellis, Inc (NUWE) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Nuwellis, Inc stock $4.18, price $5.66, upside -26.1%, quality 43 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 29, 2026.
How to read this chart
60‑month range $0.4900 – $1,000,000 · fair‑value band $2.76 – $5.22 · the $5.66 price screens above the $4.18 fair value. Dashed = 300-day average. As of Oct 29, 2026.
Follow Nuwellis in your weekly email
Every Wednesday you see whether Nuwellis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
Show moreShow less
The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients.
The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Stock analysis
Nuwellis, Inc (NUWE) currently trades at $5.66, while our model-based Fair Value estimate is $4.18, 26.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $2.76 (bear) to $5.22 (bull), the price of $5.66 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Nuwellis, Inc reported revenue of $8.3M in FY2025 versus $7.9M in FY2021, a compound +1.1%/yr. Reported net income was −$17.5M in FY2025.
Key figures
Market cap $2.2M · P/E ratio 0.0 · P/S ratio 0.24 · EPS (TTM) $3,923 · Return on equity −609% · Return on assets (EBIT) −121% · Operating margin −161% · Revenue (TTM) $9.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 96% below its 52-week high and 1,055% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at −26%, NUWE screens richer than that median.
Fair Value models
Bear$2.76Fair Value $4.18Bull$5.22
Price $5.66 · Upside -26.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3,246 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$2.76$4.18$5.2252
All 1 models by family
Asset-Based
NCAV (Graham)$2.76$4.18$5.2252
The fair value above starts from this blend and is adjusted for a stock split.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.2/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Start year 2020 (pandemic)
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.6%
’10
’14
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−228.8% (2020) → −134.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 323 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside−90.2% · Bottom 25%
Profitability
Net margin (12 months)−125.6% · Bottom 25%
Operating margin (12 months)−161.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)14.1% · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)0.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 9
FUTURE (revenue growth)71· sector 32
PAST (return on equity)0· sector 16
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 35
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nuwellis, Inc Fair Value". https://www.fairvalue-calculator.com/stock/NUWE
Frequently asked questions
Is Nuwellis, Inc (NUWE) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of $4.18 versus a price of $5.66, about −26% upside (overvalued).
What is the fair value of NUWE?
Our model-based fair value for Nuwellis, Inc is $4.18 (as of Oct 29, 2026), built from audited fundamentals. The current price: $5.66.
What is the quality score of NUWE?
Nuwellis, Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nuwellis, Inc (NUWE)?
Our model-based price target is the fair value of $4.18 (as of Oct 29, 2026) from 1 valuation models. Cautious scenario $2.76, optimistic scenario $5.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Nuwellis, Inc stock forecast for 2026?
Our models put fair value at $4.18, about −26% upside versus a price of $5.66 (overvalued). Cautious scenario $2.76, optimistic scenario $5.22. The calculation is refreshed regularly with new filings.
What is the revenue of Nuwellis, Inc (NUWE)?
Nuwellis, Inc reported trailing-twelve-month revenue of about $9.0M (latest available figure, as of Oct 29, 2026).
What is the intrinsic value of Nuwellis, Inc (NUWE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nuwellis, Inc it is $4.18 per share (as of Oct 29, 2026), against a price of $5.66. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Nuwellis, Inc stock overvalued or undervalued in 2026?
As of Oct 29, 2026, NUWE trades above its calculated fair value: price $5.66, fair value $4.18, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NUWE?
No. The price is what the market pays today ($5.66); the fair value is what the company's own numbers justify ($4.18). For Nuwellis, Inc the two are $1.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nuwellis, Inc worth?
The market values Nuwellis, Inc at about $2.2M (market capitalisation, as of Oct 29, 2026). Per share that is $5.66; our models calculate a fair value of $4.18 per share.
What do the bullish and bearish scenarios say about NUWE?
Our models span a range for Nuwellis, Inc: cautious scenario $2.76, base $4.18, optimistic $5.22 per share (as of Oct 29, 2026, price $5.66). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NUWE?
Nuwellis, Inc trades at a price-to-earnings ratio of 0.0 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.18 is built from several models across several years.
How far is NUWE from its 52-week high?
Nuwellis, Inc trades at $5.66, about 96% below its 52-week high of $146.65 and 1,055% above the low of $0.4900 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of $4.18 is for.
Which stocks are comparable to Nuwellis, Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nuwellis, Inc stock attractive at the current price?
The data as of Oct 29, 2026: price $5.66, calculated fair value $4.18 (−26%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NUWE calculated?
We run Nuwellis, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.18, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Nuwellis, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nuwellis, Inc (NUWE)?
The closing price on Oct 28, 2026 was $5.66. Our model-based fair value is $4.18, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nuwellis, Inc right now?
The price sits above even our optimistic bull case ($5.22). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($2.76 to $5.22) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Nuwellis, Inc
How large is the market capitalisation of Nuwellis, Inc (NUWE)?
The market capitalisation of Nuwellis, Inc is $2.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nuwellis, Inc (NUWE)?
The price-to-sales ratio of Nuwellis, Inc is 0.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nuwellis, Inc (NUWE)?
Earnings per share at Nuwellis, Inc are $3,923 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nuwellis, Inc (NUWE)?
The return on equity (ROE) of Nuwellis, Inc is −609% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nuwellis, Inc (NUWE)?
On an EBIT basis the return on assets of Nuwellis, Inc is −121% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nuwellis, Inc (NUWE)?
The operating margin of Nuwellis, Inc is −161% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nuwellis, Inc (NUWE)?
Revenue at Nuwellis, Inc is growing +14.1% versus a year earlier (3y avg −1.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nuwellis, Inc (NUWE) generate?
The free cash flow of Nuwellis, Inc is −$10.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nuwellis, Inc (NUWE) hold?
Nuwellis, Inc holds more cash than debt, $757K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Nuwellis, Inc in the live analysis
One click puts Nuwellis, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 29, 2026